FIELD: medicine, pharmaceutics.
SUBSTANCE: there are offered: an anti-cancer combination formed by VEGF Trap inhibitor with irinotecan and therapeutically applicable in treating neoplastic diseases, and a product containing it. What is shown is synergic action of the combination in growth inhibition of colonic carcinoma.
EFFECT: invention enables using the ingredients of the combination in lower doses vs those applicable separately, and increasing activity with reduced toxicity or inhibiting their manifestations.
3 cl, 1 tbl
| Title | Year | Author | Number |
|---|---|---|---|
| ANTICANCER COMPOSITIONS CONTAINING AGENT INHIBITING VEGF AND 5FU OR ONE OF ITS DERIVATIVES | 2005 |
|
RU2384344C2 |
| THERAPY OF TUMOURS WITH APPLICATION OF ANTIBODY TO VASCULAR ENDOTHELIAL GROWTH FACTOR AND ANTIBODIES TO HUMAN EPITHELIAL GROWTH FACTOR RECEPTOR TYPE 2 | 2007 |
|
RU2538664C2 |
| COMBINATION CONTAINING COMBRETASTATIN AND CANCER AGENTS | 2006 |
|
RU2396952C2 |
| ANTINEOPLASTIC COMPOSITIONS CONTAINING TAXANE DERIVATIVES | 2007 |
|
RU2414930C2 |
| TREATING TUMOURS WITH VEGF ANTIBODY | 2007 |
|
RU2528884C2 |
| TREATMENT WITH ANTIBODIES AGAINST VEGF | 2004 |
|
RU2519669C2 |
| THERAPEUTIC COMBINATIONS CONTAINING INHIBITOR OF POLY(ADP-RIBOSE)POLYMERASE | 2005 |
|
RU2361592C2 |
| ANTI-ANGIOGENESIS THERAPY USED FOR TREATING BREAST CANCER | 2009 |
|
RU2531948C2 |
| ANTI-ANGIOGENESIS THERAPY FOR TREATING PREVIOUSLY TREATED BREAST CANCER | 2010 |
|
RU2576027C2 |
| APILIMOD COMPOSITIONS AND METHODS OF USING THEM IN TREATING COLORECTAL CANCER | 2015 |
|
RU2739992C2 |
